Comparing Revelation Biosciences (OTCMKTS:REVB) & Edgewise Therapeutics (NASDAQ:EWTX)

Revelation Biosciences (OTCMKTS:REVBGet Rating) and Edgewise Therapeutics (NASDAQ:EWTXGet Rating) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, risk, institutional ownership, profitability and valuation.

Volatility and Risk

Revelation Biosciences has a beta of 2.79, indicating that its stock price is 179% more volatile than the S&P 500. Comparatively, Edgewise Therapeutics has a beta of -0.1, indicating that its stock price is 110% less volatile than the S&P 500.

Profitability

This table compares Revelation Biosciences and Edgewise Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Revelation Biosciences N/A N/A -12.04%
Edgewise Therapeutics N/A -18.14% -17.53%

Earnings and Valuation

This table compares Revelation Biosciences and Edgewise Therapeutics’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Revelation Biosciences N/A N/A -$2.13 million N/A N/A
Edgewise Therapeutics N/A N/A -$42.81 million ($1.03) -8.03

Institutional and Insider Ownership

73.4% of Revelation Biosciences shares are owned by institutional investors. 19.9% of Revelation Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Revelation Biosciences and Edgewise Therapeutics, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Revelation Biosciences 0 0 1 0 3.00
Edgewise Therapeutics 0 1 3 0 2.75

Revelation Biosciences presently has a consensus target price of $12.00, indicating a potential upside of 2,195.77%. Edgewise Therapeutics has a consensus target price of $22.67, indicating a potential upside of 174.08%. Given Revelation Biosciences’ stronger consensus rating and higher possible upside, analysts plainly believe Revelation Biosciences is more favorable than Edgewise Therapeutics.

Summary

Revelation Biosciences beats Edgewise Therapeutics on 8 of the 9 factors compared between the two stocks.

About Revelation Biosciences (Get Rating)

Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. The company is developing therapeutic product candidates, including REVTx-99a for the prevention or treatment of viral infections, including SARS-CoV-2, variants of SARS-CoV-2, Influenza A, Influenza B, parainfluenza, respiratory syncytial virus, rhinosinusitis, and others; REVTx-99b for the prevention or treatment of nasal congestion due to allergies or chronic rhinosinusitis; and REVTx-200, a nonclinical stage product for intranasal therapy. It is also developing lead diagnostic candidate, such as REVDx-501 to detect various respiratory viral infections. The company is headquartered in San Diego, California.

About Edgewise Therapeutics (Get Rating)

Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

Receive News & Ratings for Revelation Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revelation Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.